We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aimmune Therapeutics Inc | NASDAQ:AIMT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.49 | 34.00 | 34.49 | 0 | 01:00:00 |
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at three upcoming investor conferences in September.
Event: BioCentury NewsMakers in the Biotech IndustryDate: Friday, September 8, 2017Time: 11:00 a.m. Eastern TimeLocation: New YorkPresenter: CFO Eric Bjerkholt
Event: Bank of America Merrill Lynch Global Healthcare ConferenceDate: Friday, September 15, 2017Time: 10:40 a.m. British Summer TimeLocation: LondonPresenter: CEO Stephen Dilly, M.B.B.S., Ph.D.
Event: Cantor Fitzgerald Global Healthcare ConferenceDate: Tuesday, September 26, 2017Time: 9:10 a.m. Eastern TimeLocation: New YorkPresenter: CFO Eric Bjerkholt
Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays of the webcasts will be available for at least 30 days following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170906005590/en/
Aimmune Therapeutics, Inc.InvestorsLaura Hansen, Ph.D., 650-396-3814lhansen@aimmune.comorMediaStephanie Yao, 650-351-6479syao@aimmune.com
1 Year Aimmune Therapeutics Chart |
1 Month Aimmune Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions